Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | TYR | P14679 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7666683 | 0.89 | HCAR2 (0.48) | HCAR2KEAP1NFE2L2ALDH1A1ALOX15 | |
| SCHEMBL15781972 | 0.86 | — | — | |
| SCHEMBL3987201 | 0.79 | — | — | |
| SCHEMBL1877444 | 0.79 | — | — | |
| SCHEMBL2468754 | 0.79 | — | — | |
| SCHEMBL1877447 | 0.79 | — | — | |
| SCHEMBL7168184 | 0.77 | — | — | |
| SCHEMBL7656039 | 0.77 | — | — | |
| SCHEMBL7664566 | 0.77 | — | — | |
| SCHEMBL7664562 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111848637-B | Method for synthesizing cis/trans spiro compound containing oxygen nitrogen heteroatom | 扬州大学 | 2021-07-20 | — | — | CN | disclosed |
| CN-111848637-A | Method for synthesizing cis/trans spiro compound containing oxygen nitrogen heteroatom | 扬州大学 | 2020-10-30 | — | — | CN | disclosed |
| US-9221833-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2015-12-29 | — | — | US | disclosed |
| US-7781485-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-20070265268-A1 | Hsp90 Family protein Inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-11-15 | — | — | US | disclosed |
| EP-1813270-A1 | HSP90 FAMILY PROTEIN INHIBITORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-08-01 | — | — | EP | disclosed |
| US-6657052-B1 | Labeling DNA or RNA at a specific site consisting of stable precursor, and only becomes reactive upon activation; alkylating only phosphodiester groups; lactonization reaction traps the trialkylphosphate in a stable form. | UNIVERSITY OF ARKANSAS | 2003-12-02 | — | — | US | disclosed |
| US-5541327-A | Preparation of camptothecin analogs | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1996-07-30 | — | — | US | disclosed |
| US-5525731-A | CYCLIZATION; HALOGENATION; ALKYLATION; REDUCTION; HYDROLYSIS; DECARBOXYLATION; SELENYLATION | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1996-06-11 | — | — | US | disclosed |
| US-5446047-A | Anticancer agents | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1995-08-29 | — | — | US | disclosed |
| US-5391745-A | Cytotoxic activity towards cancer cells | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1995-02-21 | — | — | US | disclosed |
| WO-1994011376-A1 | CAMPTOTHECIN ANALOGUES AND METHODS OF PREPARATION THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1994-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265268-A1 | Hsp90 Family protein Inhibitors | HSPA4L, HSP90AB1, HSP90B1 | HCAR2 1695/4885KEAP1 478/4885NFE2L2 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.